Oxnimbi (AD109)
Apnimed (APMD)
Decision dateFeb 28, 2027
105 days away
Marketer take
An oral OSA option would reach sleep specialists and primary care in a market built around CPAP and devices, with tirzepatide already approved for OSA in adults with obesity.
- Sponsor company
- Apnimed (APMD)
- Indication
- Obstructive sleep apnea
- Therapeutic area
- Sleep, Pulmonology
- Event
- PDUFA target action date
- Date
- Feb 28, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?